Dapagliflozin Dosing for Cardiovascular and Renal Protection in Patients with Type 2 Diabetes

Introduction to Dapagliflozin Dosing

• The American College of Cardiology recommends increasing dapagliflozin to 10 mg daily for cardiovascular or renal protection in patients with eGFR 35 mL/min/1.73 m², as this dose provides evidence-based cardiorenal benefits 1, 2, 3

Critical Decision Points for Dapagliflozin Use

• Dapagliflozin is not recommended for glycemic control when eGFR <45 mL/min/1.73 m² because its glucose-lowering mechanism becomes ineffective as kidney function declines 1, 2, 4
• The evidence-based dose for cardiorenal protection is 10 mg daily, regardless of eGFR level down to 25 mL/min/1.73 m² 1, 2, 3

Clinical Algorithm for Dapagliflozin Dosing

• If the primary indication is cardiorenal protection, increase to dapagliflozin 10 mg once daily, which is safe and appropriate for eGFR ≥25 mL/min/1.73 m² 1, 2, 3
• Assess volume status carefully before increasing the dose, as dapagliflozin has diuretic effects that may be enhanced in elderly patients with hypertension 1, 4, 3

Alternative Glycemic Management Options

• GLP-1 receptor agonists (liraglutide, dulaglutide, semaglutide) require no dose adjustment and provide cardiovascular benefits at eGFR >30 mL/min/1.73 m² 2, 6
• DPP-4 inhibitors like linagliptin require no dose adjustment at any eGFR level 6
• Insulin remains effective regardless of kidney function and should be the primary glucose-lowering agent if needed 6

Safety and Efficacy Considerations

• The DAPA-CKD trial demonstrated that dapagliflozin 10 mg reduced the composite outcome of sustained eGFR decline ≥50%, end-stage kidney disease, or renal/cardiovascular death by 39% (HR 0.61, 95% CI 0.51-0.72) in patients with eGFR 25-75 mL/min/1.73 m² 1, 2, 3
• Cardiovascular death or heart failure hospitalization was reduced by 29% (HR 0.71, 95% CI 0.55-0.92) at the 10 mg dose 1, 4